Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view.

Ítems similars

• Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View
  per: Hu, Shi, et al.
  Publicat: (2013)
• Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab
  per: Liang, Shuaiyi, et al.
  Publicat: (2013)
• Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
  per: An, Qing, et al.
  Publicat: (2019)
• Molecular architecture of the ErbB2 extracellular domain homodimer
  per: Hu, Shi, et al.
  Publicat: (2015)
• Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses
  per: Liu, Boning, et al.
  Publicat: (2017)